May 1 2025
AFT Pharmaceuticals to announce full year results on Thursday May 22 2025
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) announced today that it intends to release its full year FY2025, ended March 31 2025, results on Thursday May 22 2025. The release will be issued at around 09:00 am (NZT) on the NZX and ASX.
Following the release, management will present via webinar at 10:30 am (NZT). Presentation material will be available on the company’s website AFT, the NZX website NZX and the ASX website ASX.
To participate in the upcoming earnings webinar, please pre-register with the link provided below. Webinar details will be provided upon completion of your registration.
Registration Link: AFT results presentation FY2025
For and on behalf of AFT Pharmaceuticals Limited, Malcolm Tubby, CFO.
For more information:
Investors Media
Malcolm Tubby Richard Inder
CFO, AFT Pharmaceuticals Ltd The Project
Phone: +64 9 488 0232 Phone: 021 645 643
Email: [email protected] Email: [email protected]
AFT is a growing New Zealand based multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs . Our business model is to develop and in-license products for in our markets of Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to out-license our products to local licensees and distributors to over 125 countries around the world.
For more information about the company, visit our website www.aftpharm.com.
Twiggy Forrest has a net worth over A$30b.
Armacup CEO Mark Ching steps down after 18 years.
The AI company says the move was needed to take $3.9m in liabilities off its books.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details